Loading
institutionsInstitution
UC San Diego Moores Cancer Center
San Diego's NCI comprehensive cancer centre, where the anti-GD2 antibody dinutuximab and the ROR1 antibody behind zilovertamab were developed.
Also called: Moores Comprehensive Cancer Center
Overview
NCI-designated since 1978 and comprehensive since 2001, Moores sits at the heart of the La Jolla biomedical cluster with the Salk Institute, Sanford Burnham Prebys and Scripps. Alice Yu led the Children's Oncology Group trial that established the anti-GD2 antibody dinutuximab in high-risk neuroblastoma. Thomas Kipps's CLL laboratory generated the humanised anti-ROR1 antibody (cirmtuzumab, UC-961) that became the targeting arm of the ADC zilovertamab vedotin. The centre also runs a large precision-oncology and phase 1 programme and hosts the Sanford Stem Cell Institute.
Location
La Jolla, CA, US
Type
cancer center · University of California, San Diego
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#61 · 47 points (0 Newsweek + 15 NCI + 32 from 16 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-17.
Matched to Moores Cancer Center, including child institutions. 162 works · 6,193 citations · 51% open access · 17% clinical trials · 1% reviews.
Oncology works per year
432022
422023
292024
182025
302026
Most works
- Razelle Kurzrock25 works
- Sandip Pravin Patel23 works
- Shumei Kato14 works
- Young Kwang Chae12 works
- Ramez N. Eskander11 works
- Daisuke Nishizaki10 works
- Megan Othus10 works
- Elad Sharon9 works
- Hirotaka Miyashita9 works
- Suzanna Lee9 works
Most cited
- Neuroblastoma immunotherapy (anti-GD2)
- CLL and ROR1
- Precision oncology
Diane M. Simeone
Director, Moores Cancer Center; Koman Family Presidential Director's Chair
Pancreatic cancerSurgical oncologyCancer early detection
Pancreatic cancer surgeon-scientist who directs UC San Diego Moores Cancer Center, an NCI-designated comprehensive cancer center.
Ezra E. W. Cohen
Professor of Medicine and Chief of Hematology-Oncology, UC San Diego Moores Cancer Center
Head and neck cancerImmunotherapyThyroid cancer
Led KEYNOTE-040, which showed pembrolizumab improves survival in previously treated head and neck cancer.
J. Silvio Gutkind
Associate Director, Basic Science; Professor and Chair, Department of Pharmacology
Head and neck cancerSignal transductionCancer pharmacology
Cancer pharmacologist at UC San Diego known for work on G-protein signalling and mTOR-targeted therapy in head and neck cancer.
Ludmil B. Alexandrov
Professor of Cellular and Molecular Medicine and Bioengineering, UC San Diego
Mutational signaturesCancer genomicsComputational biology
Created the mathematical framework for extracting mutational signatures from cancer genomes and the COSMIC signature catalogue.
Ramez N. Eskander
Professor of Obstetrics, Gynecology and Reproductive Sciences, UC San Diego Moores Cancer Center
Endometrial cancerImmunotherapyGynaecologic oncology surgery
Led NRG-GY018, which showed pembrolizumab with chemotherapy helps advanced endometrial cancer in both MMR-deficient and proficient disease.
Rana McKay
Associate Director, Clinical Science
Genitourinary oncologyProstate cancerKidney cancer
Genitourinary medical oncologist at UC San Diego Moores Cancer Center leading clinical science, with a strong trial record in prostate and kidney cancer.
Alice L. Yu
Professor of Pediatrics, UC San Diego; Children's Oncology Group immunotherapy investigator
NeuroblastomaAnti-GD2 antibodiesPaediatric immunotherapy
Led the trial proving that an anti-GD2 antibody improves survival in high-risk neuroblastoma.
Similar pages
- TrialCOG ANBL0032
Shares Alice L. Yu, GD2 (disialoganglioside), Dinutuximab (ch14.18) / dinutuximab beta, Children's Oncology Group (COG).
- TrialwaveLINE-003
Shares ROR1, Zilovertamab vedotin, Antibody-drug conjugate (ADC).
- PersonJulie R. Park
Shares GD2 (disialoganglioside), Dinutuximab (ch14.18) / dinutuximab beta, Children's Oncology Group (COG), Neuroblastoma (paediatric).
- InstitutionUniversity of Wisconsin Carbone Cancer Center
Shares GD2 (disialoganglioside), Dinutuximab (ch14.18) / dinutuximab beta, Children's Oncology Group (COG), Neuroblastoma (paediatric).
- PairingAnti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)
Shares GD2 (disialoganglioside), Dinutuximab (ch14.18) / dinutuximab beta, Neuroblastoma (paediatric).
- PersonRazelle Kurzrock
- TrialA Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Shares Zilovertamab vedotin, Monoclonal antibodies, Antibody-drug conjugate (ADC).
- TrialA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituxi
Shares Zilovertamab vedotin, Monoclonal antibodies, Antibody-drug conjugate (ADC).
cancers
technologies
targets
drugs
ApprovedMonoclonal antibody (anti-GD2, chimeric)
Dinutuximab (ch14.18) / dinutuximab beta · Unituxin / Qarziba (EU)
Phase 3ADC